---
_id: '7864'
abstract:
- lang: eng
  text: "Purpose of review: Cancer is one of the leading causes of death and the incidence
    rates are constantly rising. The heterogeneity of tumors poses a big challenge
    for the treatment of the disease and natural antibodies additionally affect disease
    progression. The introduction of engineered mAbs for anticancer immunotherapies
    has substantially improved progression-free and overall survival of cancer patients,
    but little efforts have been made to exploit other antibody isotypes than IgG.\r\nRecent
    findings: In order to improve these therapies, ‘next-generation antibodies’ were
    engineered to enhance a specific feature of classical antibodies and form a group
    of highly effective and precise therapy compounds. Advanced antibody approaches
    include among others antibody-drug conjugates, glyco-engineered and Fc-engineered
    antibodies, antibody fragments, radioimmunotherapy compounds, bispecific antibodies
    and alternative (non-IgG) immunoglobulin classes, especially IgE.\r\nSummary:
    The current review describes solutions for the needs of next-generation antibody
    therapies through different approaches. Careful selection of the best-suited engineering
    methodology is a key factor in developing personalized, more specific and more
    efficient mAbs against cancer to improve the outcomes of cancer patients. We highlight
    here the large evidence of IgE exploiting a highly cytotoxic effector arm as potential
    next-generation anticancer immunotherapy."
article_processing_charge: No
article_type: original
author:
- first_name: Judit
  full_name: Singer, Judit
  id: 36432834-F248-11E8-B48F-1D18A9856A87
  last_name: Singer
  orcid: 0000-0002-8777-3502
- first_name: Josef
  full_name: Singer, Josef
  last_name: Singer
- first_name: Erika
  full_name: Jensen-Jarolim, Erika
  last_name: Jensen-Jarolim
citation:
  ama: 'Singer J, Singer J, Jensen-Jarolim E. Precision medicine in clinical oncology:
    the journey from IgG antibody to IgE. <i>Current opinion in allergy and clinical
    immunology</i>. 2020;20(3):282-289. doi:<a href="https://doi.org/10.1097/ACI.0000000000000637">10.1097/ACI.0000000000000637</a>'
  apa: 'Singer, J., Singer, J., &#38; Jensen-Jarolim, E. (2020). Precision medicine
    in clinical oncology: the journey from IgG antibody to IgE. <i>Current Opinion
    in Allergy and Clinical Immunology</i>. Wolters Kluwer. <a href="https://doi.org/10.1097/ACI.0000000000000637">https://doi.org/10.1097/ACI.0000000000000637</a>'
  chicago: 'Singer, Judit, Josef Singer, and Erika Jensen-Jarolim. “Precision Medicine
    in Clinical Oncology: The Journey from IgG Antibody to IgE.” <i>Current Opinion
    in Allergy and Clinical Immunology</i>. Wolters Kluwer, 2020. <a href="https://doi.org/10.1097/ACI.0000000000000637">https://doi.org/10.1097/ACI.0000000000000637</a>.'
  ieee: 'J. Singer, J. Singer, and E. Jensen-Jarolim, “Precision medicine in clinical
    oncology: the journey from IgG antibody to IgE,” <i>Current opinion in allergy
    and clinical immunology</i>, vol. 20, no. 3. Wolters Kluwer, pp. 282–289, 2020.'
  ista: 'Singer J, Singer J, Jensen-Jarolim E. 2020. Precision medicine in clinical
    oncology: the journey from IgG antibody to IgE. Current opinion in allergy and
    clinical immunology. 20(3), 282–289.'
  mla: 'Singer, Judit, et al. “Precision Medicine in Clinical Oncology: The Journey
    from IgG Antibody to IgE.” <i>Current Opinion in Allergy and Clinical Immunology</i>,
    vol. 20, no. 3, Wolters Kluwer, 2020, pp. 282–89, doi:<a href="https://doi.org/10.1097/ACI.0000000000000637">10.1097/ACI.0000000000000637</a>.'
  short: J. Singer, J. Singer, E. Jensen-Jarolim, Current Opinion in Allergy and Clinical
    Immunology 20 (2020) 282–289.
date_created: 2020-05-17T22:00:44Z
date_published: 2020-06-01T00:00:00Z
date_updated: 2023-08-21T06:28:52Z
day: '01'
department:
- _id: Bio
doi: 10.1097/ACI.0000000000000637
external_id:
  isi:
  - '000561358300010'
intvolume: '        20'
isi: 1
issue: '3'
language:
- iso: eng
month: '06'
oa_version: None
page: 282-289
publication: Current opinion in allergy and clinical immunology
publication_identifier:
  eissn:
  - '14736322'
publication_status: published
publisher: Wolters Kluwer
quality_controlled: '1'
scopus_import: '1'
status: public
title: 'Precision medicine in clinical oncology: the journey from IgG antibody to
  IgE'
type: journal_article
user_id: 4359f0d1-fa6c-11eb-b949-802e58b17ae8
volume: 20
year: '2020'
...